SCHEMBL3234471

SCHEMBL3234471

CN1CCN(c2ccc3ccccc3c2)c2ccc(-c3ccc(N)nn3)cc2C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.57
SLC6A3 Q01959 2/20 0.57
SLC6A4 P31645 1/20 0.57
SCN9A Q15858 2/20 0.48
HTR3A P46098 1/20 0.42
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
MAPT P10636 1/20 0.39
XBP1 P17861 1/20 0.39
RAB9A P51151 1/20 0.39
KLF5 Q13887 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HTR6 P50406 4/20 0.35
HTR1A P08908 3/20 0.35
HTR2A P28223 3/20 0.35
HTR7 P34969 3/20 0.35
DRD2 P14416 1/20 0.35
PDK1 Q15118 1/20 0.35
PDK2 Q15119 1/20 0.35
PDK3 Q15120 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3225653 0.90 SCN9A (0.46) SLC6A2SLC6A3SLC6A4SCN9AHTR3A
SCHEMBL3223059 0.89 SCN9A (0.45) SLC6A2SLC6A3SLC6A4SCN9AHTR3A
SCHEMBL3228409 0.88 SLC6A2 (0.49) SLC6A2SLC6A3SLC6A4SCN9AHTR3A
SCHEMBL3231955 0.86 SCN9A (0.55) SLC6A2SLC6A3SLC6A4SCN9AHTR3A
SCHEMBL3479672 0.86 SCN9A (0.45) SLC6A2SLC6A3SLC6A4SCN9AHTR3A
SCHEMBL3230133 0.86 SCN9A (0.51) SLC6A2SLC6A3SLC6A4SCN9AHTR3A
SCHEMBL3235921 0.86 SCN9A (0.45) SLC6A2SLC6A3SLC6A4SCN9AHTR3A
SCHEMBL3479582 0.85 SLC6A2 (0.55) SLC6A2SLC6A3SLC6A4SCN9AHTR3A
SCHEMBL3231072 0.84 SCN9A (0.44) SLC6A2SLC6A3SLC6A4SCN9AKDM4E
SCHEMBL3229179 0.84 SCN9A (0.46) SLC6A2SLC6A3SLC6A4SCN9APDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed
EP-2146722-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR Technology, Inc. (US) 2010-01-27 EP disclosed
WO-2008141081-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR TECHNOLOGY, INC. (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SLC6A2 28/4885SLC6A3 32/4885SLC6A4 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.